Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of long-chain non-coding RNA MALAT1, HIF1A-AS1 and XIST of plasma in non-small cell lung cancer early diagnosis kit

A technology of HIF1A-AS1 and non-small cell lung cancer, applied in the field of biomedicine, can solve the problems of low specificity and poor sensitivity, and achieve the effect of high sensitivity, low cost and simple operation

Inactive Publication Date: 2019-01-18
深圳瑞科生物科技有限公司
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since the use of a single lncRNA as a detection index has the defects of low specificity and poor sensitivity, the present invention simultaneously performs joint detection of multiple lncRNAs and becomes the key to improving specificity and sensitivity
There is no research and application of MALAT1, HIF1A-AS1 and XIST in the early diagnosis of non-small cell lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of long-chain non-coding RNA MALAT1, HIF1A-AS1 and XIST of plasma in non-small cell lung cancer early diagnosis kit
  • Application of long-chain non-coding RNA MALAT1, HIF1A-AS1 and XIST of plasma in non-small cell lung cancer early diagnosis kit
  • Application of long-chain non-coding RNA MALAT1, HIF1A-AS1 and XIST of plasma in non-small cell lung cancer early diagnosis kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] (1) Select 30 cases of non-small cell lung cancer patients and 30 cases of normal people, and carry out detection according to the above method. The results are shown in Tables 1, 2 and 3:

[0051] group

Relative expression of MALAT1

Non-small cell lung cancer patients

35.13±2.15

normal person

28.63±3.02

[0052] Table 1: Relative expression of MALAT1 in the blood of patients with non-small cell lung cancer and normal people

[0053] group

Relative expression of HIF1A-AS1

Non-small cell lung cancer patients

23.85±4.13

normal person

36.77±3.76

[0054] Table 2: Relative expression of HIF1A-AS1 in the blood of non-small cell lung cancer patients and normal people

[0055]

[0056]

[0057] Table 3: Relative expression of XIST in the blood of patients with non-small cell lung cancer and normal people

[0058] Show by above-mentioned embodiment:

[0059] If the ratio of the relative express...

Embodiment 2

[0061] Randomly select 10 patients with non-small cell lung cancer and 10 normal people, and detect according to the method of the present invention. It is lower than 0.65 and 0.56, indicating that the expression levels of MALAT1, HIF1A-AS1 and XIST in plasma have very high specificity and sensitivity for early diagnosis of non-small cell lung cancer.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of long-chain non-coding RNA MALAT1, HIF1A-AS1 and XIST of plasma in non-small cell lung cancer early diagnosis kit. The application of AS1 and XIST in early diagnosis of non-small cell lung cancer is to detect MALAT1, HIF1A in plasma by real-time fluorescent quantitative PCR. The relative expression levels of AS1 and XIST (GAPDH as internal reference), used forscreening of early non-small cell lung cancer in high-risk population of non-small cell lung cancer, has the advantages of high sensitivity, strong specificity, simple operation and low cost.

Description

technical field [0001] The invention belongs to the field of biomedicine, and particularly relates to the application of long-chain non-coding RNA MALAT1, HIF1A-AS1 and XIST in plasma in an early diagnosis kit for non-small cell lung cancer. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality worldwide. In 2017, the number of new cases of lung cancer in my country reached 800,000, and the death toll was nearly 700,000, accounting for a quarter of all cancer deaths. This figure is still growing at an annual rate of 26.9%, and it is expected to reach 1 million by 2025. people. Clinically, about 85% of lung cancers are non-small cell lung cancers, and the 5-year survival rate is less than 15%. Due to the limitations of early diagnosis methods, more than 75% of patients missed the best period of surgical treatment, resulting in a high mortality rate of non-small cell lung cancer. Therefore, in addition to taking further measu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/158C12Q2600/166C12Q2600/178
Inventor 杨敏刘俊刘义
Owner 深圳瑞科生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com